Literature DB >> 3767545

Renal interstitial fibrosis and vascular changes. Occurrence in patients with autoimmune diseases treated with cyclosporine.

K Svenson, S O Bohman, R Hällgren.   

Abstract

Histologic examinations of kidney biopsy specimens from six patients with relapsing polychondritis (n = 1), Behçet's syndrome (n = 3), and chronic uveitis (n = 2) were performed after four to 36 months of treatment with cyclosporine. Five of the patients had a variable degree of focal interstitial fibrosis and tubular atrophy, with and without minimal interstitial inflammation. Arteriolar hyalinization was noted in four and glomerular sclerosis in two patients. These renal lesions could not be attributed to underlying autoimmune disease or previous drug therapy but were similar to those recently reported in kidney and heart recipients receiving long-term cyclosporine. The initial cyclosporine doses were 15 mg/kg body weight in one patient and 10 mg/kg in the others. The maintenance cyclosporine doses ranged from 2.5 to 7.5 mg/kg with appropriate trough cyclosporine plasma levels (60 to 130 ng/mL). A rough correspondence between the extent of the histologic renal changes and the cumulative cyclosporine was seen, whereas serum creatinine increase or the development of hypertension during treatment did not predict the degree of interstitial fibrosis or the presence of arteriolar changes. Neither did a rapid fall in the serum creatinine level after withdrawal of cyclosporine exclude focal irreversible renal lesions. Since the histopathologic changes found in the kidneys are potentially progressive, we believe that, until more is known, long-term cyclosporine treatment should be reserved for situations where more established immunosuppression has failed to control an autoimmune process threatening the function of vital organs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3767545

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  8 in total

1.  Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial.

Authors:  Y Ozyazgan; S Yurdakul; H Yazici; B Tüzün; A Işçimen; Y Tüzün; T Aktunç; H Pazarli; V Hamuryudan; A Müftüoğlu
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

2.  Cyclosporin in the treatment of severe chronic idiopathic uveitis.

Authors:  J de Vries; G S Baarsma; M J Zaal; T N Boen-Tan; A Rothova; H J Buitenhuis; C M Schweitzer; R J de Keizer; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1990-06       Impact factor: 4.638

3.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

Review 4.  Primary care of the renal transplant patient.

Authors:  J D Pirsch; R Friedman
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

Review 5.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

6.  Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A.

Authors:  T A McCulloch; S J Harper; P K Donnelly; J Moorhouse; P R Bell; J Walls; J Feehally; P N Furness
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

7.  Combined steroid-cyclosporin treatment of chronic autoimmune diseases. Clinical results and assessment of nephrotoxicity by renal biopsy.

Authors:  P A Miescher; H Favre; F Chatelanat; M J Mihatsch
Journal:  Klin Wochenschr       Date:  1987-08-03

8.  Ocular penetration of cyclosporin A. III: The human eye.

Authors:  D BenEzra; G Maftzir; C de Courten; P Timonen
Journal:  Br J Ophthalmol       Date:  1990-06       Impact factor: 4.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.